All In Biotech

NDA 021897 · Alkermes

Vivitrol

Naltrexone · Intramuscular

Priority review

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Apr 13, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

478

101 Phase 3, 23 recruiting

FAERS reports

31,043

8,878 serious, 1,344 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 31, 2026.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support. VIVITROL contains naltrexone, an opioid antagonist, and is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration ( 1.1 ). VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification ( 1.2 ). VIVITROL should be part of a comprehensive management program that includes psychosocial support ( 1 ). 1.1 Alcohol Dependence VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration. 1.2 Opioid Dependence VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification.

Mechanism: Naltrexone is an opioid antagonist with highest affinity for the mu opioid receptor. Naltrexone has little or no opioid agonist activity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VIVITROL · NALTREXONE 380MG/VIAL · FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Naltrexone" as an intervention, any sponsor and status, largest first.

All 478 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injection site reaction4,410
  • injection site pain3,180
  • nausea2,165
  • alcoholism1,959
  • injection site mass1,927
  • fatigue1,824
  • pain1,671
  • drug ineffective1,580
  • off label use1,525
  • headache1,516
  • feeling abnormal1,412
  • drug dependence1,378

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200536
200623
200752
200862
200938
201051
201155
2012123
2013151
2014281
20151,180
20161,861
20172,273
20186,405
20193,346
20203,695
20212,783
20222,581
20231,962
20241,465
20251,428
20261,185

Recalls

4 FDA enforcement reports for this application.

  • Sep 26, 2019 · Class II · Terminated

    Labeling: Not Elsewhere Classified. Drug product kit recalled due to 1 inch needles being placed in the 1 1/2 inch needle cardboard sleeve labelled as administration needles. The product vial is not impacted.

  • Aug 8, 2019 · Class II · Terminated

    Labeling: Not Elsewhere Classified. Drug product kit recalled due to 1 inch needles being placed in the 1 1/2 inch needle cardboard sleeve labelled as administration needles. The product vial is not impacted.

  • Mar 4, 2014 · Class II · Terminated

    Customer complaints for failure to deliver the dose.

  • Nov 6, 2012 · Class II · Terminated

    Lack of Assurance of Sterility: Product did not meet the criteria for container closure integrity testing during routine 24 month stability testing.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vivitrol (Naltrexone Microspheres)

2024 spending

$73.1M

Beneficiaries

9,867

44,521 claims

Per beneficiary

$7,408

$1,621.97 per unit

View as table
YearSpending
2020$36,655,227
2021$43,303,110
2022$50,748,174
2023$62,245,696
2024$73,090,051

Part B: Vivitrol (Naltrexone Microspheres) · HCPCS J2315

2024 spending

$2.6M

Beneficiaries

601

2,228 claims

Per beneficiary

$4,344

2024 ASP limit $4.03 per unit

View as table
YearSpending
2020$1,711,448
2021$2,075,658
2022$2,478,785
2023$2,324,438
2024$2,611,004

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,504 on PubMed

Sponsor: Alkermes

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.